L. Bubendorf

Discipline

Histoire, Philosophie et Sociologie des sciences (2)

Type de document

Articles (8)

Co-auteur

Date

Source

Mot-clé

Patients (6) Human beings (6) Cancer (6) Patients (6) survie (5) Survival (5) thérapie (4) analyse (4) Treatment (4) Inhibitors (4) Therapeutics (4) Theater (4) Lungs--Cancer (4) Drama (4) Acting (4) Analysis (4) protocole (3) perte (3) procès (3) cancer (3) Diagnosis (3) Chemotherapy (3) Cancer (3) Tumors (3) Prostate (3) Lungs (3) Impact (3) Diagnosis (3) Chemotherapy (3) Cells (3)

Documents écrit par L. Bubendorf (8) | parle de L. Bubendorf (0)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
D. König et al. (11 juil. 2023)
DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
J. Gallon et al. (14 avr. 2023)
Alterations in homologous recombination repair genes in prostate cancer brain metastases.
A. Rodriguez-Calero et al. (3 mai 2022)
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future.
P. Hofman et al.
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
A. Curioni-Fontecedro et al.
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
U. Rulle et al.
ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma
C. Zenzmaier et al. (30 déc. 2011)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G. et al. (2008)